Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation

Clinical and Molecular Hepatology

Volumn 20, Issue 2, 2014, Pages 192-203

  Lee, Ju Yeun ^a,b   Kim, Yul Hee ^c   Yi, Nam Joon ^d   Kim, Hyang Sook ^a   Lee, Hye Suk ^a   Lee, Byung Koo ^c   Kim, Hyeyoung ^d   Choi, Young Rok ^d   Hong, Geun ^e   Lee, Kwang Woong ^d   Suh, Kyung Suk ^d  

^a Seoul National University Hospital   (South Korea)

^b Hanyang University   (South Korea)

^c Ewha Womans University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

Author keywords

18F PET scan; AFP; Basiliximab; Immunosuppression; Microvascular invasion; PIVKA II

Indexed keywords

ALPHA FETOPROTEIN; ANTIVITAMIN K; BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; IMMUNOSUPPRESSIVE AGENT; PROTEIN PRECURSOR; PROTHROMBIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; MODEL FOR END STAGE LIVER DISEASE SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROTEIN PRECURSORS; PROTHROMBIN; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84925229578     PISSN: 22872728     EISSN: 2287285X     Source Type: Journal    
DOI: 10.3350/cmh.2014.20.2.192     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl Int 2013;26:109-118.
3. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002;8:736-748.
4. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression? Transplantation 2002;74:1746-1751.
5. Fiorentino M, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004;10:1789-1795.
6. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007;13:543-551.
7. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008;248:857-862.
8. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-534.
9. Chen ZS, He F, Zeng FJ, Jiang JP, Du DF, Liu B. Early steroid withdrawal after liver transplantation for hepatocellular carcinoma. World J Gastroenterol 2007;13:5273-5276.
10. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimusbased immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010;51:1237-1243.
11. U.S. Food and Drug Administration (FDA). Rapamune highlights of prescribing information. FDA web site, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021083s045,021110s052lbl.pdf. Accessed 2013.
12. Kwekkeboom J, Tha-In T, Tra WM, Hop W, Boor PP, Mancham S, et al. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation. Am J Transplant 2005;5:2393-2402
13. Yi NJ, Lee KW, Kong SY, Park KU, Lee KB, Hong G, et al. Outcome of various treatments for posttransplant hepatitis B virus recurrence. World J Surg 2013;37:812-819
14. Ramirez CB, Bozdin A, Frank A, Maley W, Doria C. Optimizing use of basiliximab in liver transplantation. Transplant Research and Risk Management 2010;2:1-10.
15. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-1660.
16. Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy: a retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg 1989;209:88-98.
17. Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol 2010;25:1217-1226.
18. Bruix J, Sherman M; Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
19. Cescon M, Ravaioli M, Grazi GL, Ercolani G, Cucchetti A, Bertuzzo V, et al. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010; 2010. pii:904152
20. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-540.
21. Majno P, Giostra E, Mentha G; Geneva liver cancer study. Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma? J Hepatol 2005;43:577-584.
22. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006;12:7319-7325.
23. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc 2006;38:3633-3635.
24. Gruttadauria S, Vasta F, Mandala L, Cintorino D, Piazza T, Spada M, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 2005;37:2611-2613.
25. Chapman TM and Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drug 2003;63:2803-2835.
26. Okita R, Yamaguchi Y, Ohara M, Hironaka K, Okawaki M, Nagamine I, et al. Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int J Oncol 2009;34:563-572.
27. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999;57:207-213.
28. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010;89:227-231.
29. Montaser LM, Abbas OM, Saltah AM, Waked IA. Circulating AFP mRNA as a possible indicator of hematogenous spread of HCC cells: a possible association with HBV infection. J Egypt Natl Canc Inst 2007;19:48-60.
30. Lee KW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. J Korean Soc Transplant 2010;24:4-12.
31. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009;9:2362-2371.
32. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, Aishima S, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007;95:235-240.
33. Salizzoni M, Romagnoli R, Lupo F, David E, Mirabella S, Cercutti E, et al. Microscopic vascular invasion detected by anti-CD34 immunohistochemistry as a predictor of recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2003;76:844-848.
34. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086.
35. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-1092.
36. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536.